PSS39 Assessment of the Health Status Using the 12-Item Medical Outcomes Study Short Form (SF-12) Questionnaire (2578 Dermatological Out-Patients)  by Tabolli, S. et al.
ranged between €9.44 (UK) and €121.17 (Sweden); mean direct non-medical costs
were €2.85/episode. Indirect costs contributed significantly to the total cost/epi-
sode in Italy (81.4%; €91.14), UK (79.8%; €37.55), Germany (60.0%; €26.74) and Sweden
(59.5%; €182.07), whereas indirect costs contributed only 14.7% (€3.54) in Spain,
where the value associated with absence from work/school was low.
CONCLUSIONS: AOM was associated with substantial economic burden in these
European countries. The cost per episode and the contribution of direct/indirect
costs varied between countries, potentially reflecting socio-economic differences
and variation in AOM management.
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OBJECTIVES: Highlight the action of two analgesics combining paracetamol and
codeine (Klipal 600® and EfferalganDafalgan Codeine®), with a minimum of 50 mg
of codeine at a time. METHODS: Multicentre, longitudinal, prospective, observa-
tional study, performed in metropolitan France from data collected by the dental
surgeons that have accepted to participate in it. RESULTS: A total of 105 patients
were included. Klipal 600® was prescribed for 76 of them versus 24 for the other
group. 56.2% of the patients are women. The average age is 45.57  14.64. The
measurement of the average pain intensity, evaluated each day over a 6 day period
by a VAS, shows an insignificant difference at the inclusion between the 2 groups (p
 0.23). But, contrary to the Efferalgan/Dafalgan codeine® group, the score differ-
ential for the pain intensity is statistically significant between Day 1 and Day 2 with
the Klipal 600® group and the improvement is significant up to the fourth day. The
pain qualification was evaluated by the Saint Antoine pain questionnaire (abbre-
viated format) bearing on 16 sensory and emotional qualifiers specifying the de-
scription of the pain experienced. The difference is not significant between the 2
groups at the inclusion (p  0.09), then it is observed that the pain qualification
score is reduced beginning on the second day for the 2 groups. For the 2 groups, it
is observed that the average number of tablets is in the order of 2.3 during the first
48 hours with a similar progressive decrease up to the sixth day. The prescription
of one tablet at a time for the Klipal® is an advantage for the follow up of the
treatment and its effectiveness.CONCLUSIONS: In reality, this study demonstrates
a quicker improvement in pain in the Klipal® group, also associated with reduced
consumption of the treatment and a better effectiveness.
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OBJECTIVES: To assess whether the SF-12 questionnaire could yield a valid de-
scription of the health status of a large number of dermatological out-patients.
METHODS:The SF-12 and the 12-item General Health Questionnaire (GHQ-12) were
utilized. Questionnaires were self-completed by the out-patients in the waiting
rooms of a dermatological hospital. At the end of the visit the dermatologists re-
corded the diagnosis and the evaluation of the clinical severity. RESULTS: Data
were complete for 2.578 patients. We observed a reduction in the Physical Compo-
nent Summary score (PCS-12) with increasing age, while the Mental Component
Summary score (MCS-12) was stable. PCS-12 and MCS-12 scores were worse in
women. For the MCS-12 scores, the lowest mean values were seen in the group of
patients with dermatitis, and were dramatically lower in almost all the diseases
observed compared to the scores reported for non-dermatological conditions and
to the normative values. 23% of patients were identified as GHQ-12 positive.
GHQ-12 positives had lower PCS-12 and MCS-12 scores compared to GHQ-12 neg-
atives (mean values, PCS: 48.34.8 vs. 44.56.5; MCS: 43.96.7 vs. 39.47.0, respec-
tively). PCS-12 and the MCS-12 mean values were lower for GHQ-12 “cases” in all
diseases, independently from the level of clinical severity of the disease.
CONCLUSIONS: The impact of the dermatological diseases is dramatically high for
the mental components of the health status; the mean values of MCS-12 were very
low, and when compared to other relevant conditions only tumours and nervous
system diseases showed lower values. The use of the generic SF-12 and GHQ-12
questionnaires allowed to have a clear picture of the health status of dermatolog-
ical patients, to compare different diseases within the dermatological specialty,
and to make comparisons between skin conditions and other non-dermatological
diseases.
PSS40
THE EFFECT OF ACUTE OTITIS MEDIA IN CHILDREN ON PARENTS’ QUALITY OF
LIFE: DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE IMPLEMENTED
IN A PROSPECTIVE OBSERVATIONAL COHORT STUDY IN EUROPE
Liese JG1, Giaquinto C2, Silfverdal SA3, Carmona A4, Larcombe J5, Garcia-sicilia J6,
Fuat A7, Muñoz Hiraldo E8, Arroba basanta ML9, Sloesen B10, Vollmar J11, Holl K10,
Pirçon JY10, Rosenlund M10
1University Children’s Hospital, Würzburg, Germany, 2University of Padova, Padova, Italy,
3Umeå University, Umeå, Sweden, 4Instituto Hispalense de Pediatria, Sevilla, Spain, 5Harbinson
House Surgery (Sedgefield) and University of Durham, Durham, UK, 6Hospital Materno-Infantil
Universitario La Paz, Madrid, Spain, 7Carmel Medical Practice (Darlington) and University of
Durham, Durham, UK, 8Health Centre Dr Castroviejo, Madrid, Spain, 9Universidad Autónoma de
Madrid, Madrid, Spain, 10GlaxoSmithKline Biologicals, Wavre, Belgium, 11GlaxoSmithKline
GmbH & Co. K.G., Munich, Germany
OBJECTIVES: Acute otitis media (AOM) is one of the commonest paediatric bacte-
rial infections and is often recurrent. AOM may impact upon parents’ quality of life
(QoL), but there are currently no validated tools devoted specifically to measuring
this impact.METHODS: An AOM-specific questionnaire was developed, based on a
published questionnaire measuring the effect of children’s recurrent ear, nose and
throat infections on parents’ QoL. Fourteen AOM-related questions were grouped
into three scores: emotional score (ES; eight items), daily disturbance score (DDS;
six items) and total score (TS; 14 items). A fifteenth generic question assessed
overall quality of life (global score; GS). Responses were measured using a five-
point Likert scale; higher scores indicate greater impact on QoL. Validation of the
questionnaire followed a standard procedure for QoL tools, with multitrait analy-
ses and internal consistency reliability using Cronbach’s alpha. The tool was ap-
plied in a large, prospective, observational cohort study including 5882 healthy
children aged6 years enrolled from 73 medical practices in Germany, Italy, Spain,
Sweden and the UK, 1113 of whom experienced a total of 1419 AOM episodes during
follow-up. RESULTS: The questionnaire was completed for 1063 episodes (75%).
The item convergent and discriminant validity criteria were met successfully. The
homogeneity and satisfactory consistency of the GS showed correlations between
0.4 and 0.6 for 12 items. The internal consistency reliability of the questionnaire
was assessed as “good” or “excellent”. All scores had a mean around 30/100 (ES:
30.49 [SD: 20.30]; DDS: 29.35 [SD: 21.99]; TS: 30.00 [SD: 19.37]; GS: 30.02 [SD: 26.24])
and increased significantly with AOM severity, assessed by parents using a faces
scale tool (AOM-FS). CONCLUSIONS: An AOM-specific parental QoL questionnaire
was successfully developed and validated, demonstrating good performance
across five European countries. Correlation was observed between AOM severity
and QoL scores.
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OBJECTIVES: Estimate the impact of psoriasis on quality of life of patients accord-
ing to clinical features of the disease. METHODS: Patients 18 years with a diag-
nosis of plaque psoriasis. Variables: demographic and clinical data, health status
perceived by the patient and quality of life (QoL) questionnaires specific for psori-
asis: PDI (15 items with 4 response options, and overall result from 0minimal
impact to 45maximum impact) and PSO-LIFE (20 items, with a timeframe of 7
days, are answered on a 5-point Likert scale (from Always to Never) and the
overall result ranging from 0 maximum impact to 100minimal impact).
RESULTS: A total of 304 patients were included (182 with active-psoriasis and 122
with inactive-psoriasis), mean age 44 (SD15) years and 56% men. The mean time
from psoriasis diagnosis was 18 years (SD12), the mean weight 76 (SD16.5) kg,
the PASI index was 17 (SD7.4) for active-psoriasis and 5.6 (SD5.3) for inactive-
psoriasis; 47% of active-psoriasis and 7.5% of inactive-psoriasis patients reported
their overall health status as being rather, quite or very poor. Two question-
naires show a poorer QoL in patients with active-psoriasis compared with those
with inactive-psoriasis: PDI of 8.3 (SD8.1) against 3.6 (SD5.5), and PSO-LIFE 57.4
(SD20.4) versus 76.4 (SD20.6) respectively. There is a correlation between PASI
and PSO-LIFE score (r-0.43;p0.01) and patients with visible affected areas such
as head or upper limbs showed greater impact in QoL (63;SD22) compared with
trunk and lower limbs (74.8,SD24) or patients not affected at the time of inclusion
in the study (78.5;SD21.6). After adjusting by age, education and duration of the
last psoriasis episode, there are significant differences in PSO-LIFE scores between
patients with active and inactive psoriasis (p0.01). CONCLUSIONS: The quality of
life in patients with psoriasis is affected especially in patients with active psoriasis
and in patients with localized lesions in visible areas.
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OBJECTIVES: To test the efficacy an “emotional writing” exercises to improve qual-
ity of life of patients with psoriasis undergoing systemic treatments. METHODS:
This study was designed as a controlled randomized intervention. Seven Clinical
centers in Italy were involved. The intervention group (n  100) wrote about the
most stressful event in their life for three sessions of 20 minutes each. The Control
group (n 100) received only the educational materials that were also given to the
intervention group. The recruitment time was twelve months, and the follow-up
time was also 12 months. The SF-12, GHQ-12, Skindex_29, and PASI scores were
evaluated at baseline and after 1, 6, and 12 months. Data were analyzed using
Generalized Estimating Equations model. RESULTS: Ninety-seven patients were
allocated to the Writing group and 105 to the Control group. forty-two patients of
the first group and 49 of the control group reached the 12-mont follow-up visit. Data
were consistent with the expected improvement after the start of treatment as
observed at the different follow-up times: the severity of psoriasis decreased, the
impact of psoriasis on quality of life decreased, and the health status improved
both for the physical and mental components.The proportion of patients reaching
PASI-50 (i.e., a reduction of 50% in the PASI score) observed at different follow-up
times was similar in the two study groups and was not associated with any of the
examined demographic variables. No advantage was observed for the intervention
group also in terms of QoL and general health status. CONCLUSIONS: The longitu-
dinal analysis did not prove relevant differences between the group receiving ed-
A509V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
